Merck may be near NuvaRing settlement

Share this article:

Merck may be poised to settle lawsuits over its NuvaRing contraceptive for $100 million—a bargain, Bloomberg notes, compared to drugmakers such as Bayer, which has paid more than $1.6 billion over claims surrounding its birth control pills Yaz and Yazmin.

Women and families have sued the company, saying the drugmaker knew the contraceptive triggered a higher risk of heart attack and blood clots than competing products. Merck told Bloomberg that the proposed settlement is not an admission of wrongdoing and the company stands behind the contraceptive.

Ninety-five percent of the 3,800 plaintiffs need to agree to the settlement or Merck can walk away.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.